Business
Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care
Helix, a leader in precision health, today announced a partnership with leading cancer diagnostics company Veracyte that will make it easier for urologists to add comprehensive germline testing for patients with high-risk localized and metastatic prostate cancer. Through this collaboration, Helix's whole-exome based hereditary cancer test will be available alongside Veracyte's Decipher® Prostate test, enabling a more complete view of each patient's cancer biology and inherited risk.
About this update from Veracyte, Inc.
[{"type":"text","content":"Collaboration brings whole-exome based hereditary cancer insights to urologists and their patients by offering it alongside Veracyte's Decipher Prostate Test","length":161,"tagName":"p","attribs":{}},{"type":"text","content":"SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Helix, a leader in precision health, today announced a partnership with leading cancer diagnostics company Veracyte that will make it easier for urologists to add comprehensive germline testing for patients with high-risk localized and metastatic prostate cancer. Through this collaboration, Helix's whole-exome based hereditary cancer test will be available alongside Veracyte's Decipher® Prostate test, enabling a more complete view of each patient's cancer biology and inherited risk.","length":547,"tagName":"p"},{"type":"image","alt":"Helix (PRNewsfoto/Helix Inc)","displaySize":"","headline":null,"caption":"Helix (PRNewsfoto/Helix Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":96,"url":"https://media.zenfs.com/en/prnewswire.com/4b1e8c7bae79d4d3228584a3d9777c1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/95oy24WhwklQbr_swsnabQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4b1e8c7bae79d4d3228584a3d9777c1c","width":400,"height":96}},"href":"https://mma.prnewswire.com/media/1397195/Helix_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The partnership was also highlighted during Veracyte's earnings call, reinforcing the shared commitment to expanding access to clinically actionable genomic insights in prostate cancer care.","length":194,"tagName":"p"},{"type":"text","content":"The National Comprehensive Cancer Network® (NCCN®) guidelines recommend germline genetic testing for patients with metastatic and high-risk localized prostate cancer. Germline findings can influence therapeutic decision-making, including the use of targeted therapies like PARP inhibitors. The integration of Helix's hereditary cancer test into the Decipher ordering workflow gives physicians a convenient way to access this important information and deliver more personalized care.","length":486,"tagName":"p"},{"type":"text","content":""Patients diagnosed with cancer deserve seamless access to genomic insights that can improve their care – not ...